Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC before second lung volume reduction surgery in severe emphysema
NL-OMON33080Phase 1Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone-marrow mesenchymal stem cells in emphysema and chronic obstructive pulmonary disease (COPD), sponsored by Leiden University Medical Center. Primary endpoints: Safety and feasibility of intravenous BM-MSC infusion and Change in lung function versus historical LUMC cohort. Started Sep 2010; status: active, not recruiting.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
emphysemachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON33080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33080.